Shiton

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Shiton

What is Shiton? Defining the Hormonal Drug Entity

Property Description
Active Ingredient Norethisterone (Norethindrone)
Form Oral Tablet
Pharmacological Class Progestin (Progestogen)
Common Use Hormonal regulation
Origin Synthetic

Shiton is a hormonal drug defined by its sole active ingredient, Norethisterone (also known as Norethindrone), and is classified as a synthetic progestin. This medication is a single-ingredient product typically taken in the form of an oral tablet. Its role as a second-generation progestin distinguishes it from older analogues, offering predictable pharmacological characteristics.

The identity of Shiton centers on the chemical structure of Norethisterone, a synthetic compound that is clinically recognized for mimicking the fundamental progestogenic activity of progesterone, the natural female hormone. Norethisterone is a progestin utilized in hormonal therapy. As a Progestogen, this compound is chemically altered to provide reliable biological effects when administered orally, making it suitable for systemic use. The goal of this medication is to provide precise hormonal regulation within the female reproductive system.


Composition and General Purpose: What is Shiton Made Of?

Shiton is presented as an oral tablet and is characterized as a progestin-only monotherapy. Its composition consists of the active ingredient, Norethisterone, combined with solid pharmaceutical excipients necessary to create the stabilized dosage form. Chemically, Norethisterone is an ethinylated 19-nortestosterone derivative. This specific chemical derivation allows the substance to be effective when taken by mouth.

This progestin-only composition is significant because it focuses the drug's action on the progesterone receptor system. By acting as a Progesterone Receptor Agonist, Shiton is able to suppress key reproductive functions through an antigonadotropic effect, and it alters the state of the uterine lining. The general purpose of this targeted action is to provide management for hormone-mediated processes, used primarily to manage the menstrual cycle and prevent pregnancy.

Regulatory References

  1. Norethindrone: MedlinePlus Drug Information
  2. WHO Model Lists of Essential Medicines

What side effects are possible with Shiton?

Possible Side Effects and Safety Information

The safety profile of Norethisterone (Shiton) is derived from official government regulatory documents, which classify adverse reactions according to frequency and body system affected.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Documented Effects
Very Common Irregular uterine bleeding and spotting. These effects are particularly frequent during the initial months of treatment.
Common Headache, nausea, mood changes, breast discomfort, depression, dizziness, and weight increase.
Less Common/Rare Serious vascular events, including thromboembolism, are classified in these categories.

System-Organ-Class Groupings

The drug's effects are officially grouped across several system-organ classes (SOCs). These include Reproductive System and Breast Disorders (e.g., changes in bleeding patterns), Nervous System Disorders (e.g., migraine), Psychiatric Disorders (e.g., depression, altered libido), and Skin and Subcutaneous Tissue Disorders (e.g., acne, hirsutism). Changes to Metabolism and Nutrition (e.g., fluid retention, weight change) are also documented in the regulatory safety information.

Serious Adverse Reactions and Safety Restrictions

Official labeling documents specific safety concerns and restrictions. Serious adverse reactions noted in the regulatory text include the potential for thromboembolic events (such as deep vein thrombosis and pulmonary embolism) and a documented association with hepatic tumours (both benign and malignant).

Use is formally restricted in individuals with a history of or current thromboembolic disorders, known or suspected hormone-dependent malignancies (such as breast cancer), and active severe hepatic disease. Furthermore, Norethisterone is generally contraindicated during pregnancy as documented in regulatory safety information.

Overdose and Emergency Response

Overdose and when to seek help for Shiton

The following information is strictly derived from official governmental regulatory documents (e.g., FDA Prescribing Information, EMA Summary of Product Characteristics, Health Canada monographs).

Overdose Scope

Classification Area Official Regulatory Statement
Documented Overdose Presentations No specific signs, symptoms, or clinical manifestations related to an overdose of the product Shiton are documented in the available governmental regulatory literature.
Physiological Systems Affected No specific physiological systems are officially documented in the overdose context for this product in regulatory labeling.
Dose-Related Factors No specific toxic dose, supratherapeutic dose, or substance factors associated with overdose risk for this product are officially labeled.
Population-Specific Overdose Notes No population or condition-specific overdose risks are explicitly stated in official regulatory labeling for this product.
Emergency-Response Statements No explicit, product-specific procedural instructions for emergency response are documented in official regulatory sources.
When Immediate Medical Help is Required No explicit, product-specific phrasing for when to seek urgent medical attention is documented in official regulatory sources.

Resulting Overdose Structure

  • Official Overdose Statement: Official regulatory documents do not provide a product-specific profile detailing the signs or symptoms of an overdose with Shiton.
  • Antidote/Management: No specific antidote or documented management measures for an overdose with this product are included in government-approved prescribing information.

Connection to the overall overdose profile: The absence of a documented regulatory overdose profile for Shiton in authoritative sources signifies that no officially verified information on its toxic effects, associated clinical manifestations, or mandated emergency response procedures exists in government-approved prescribing information. No regulatory determination has been established regarding the specific circumstances under which urgent medical attention should be sought for this product.

Therapeutic Uses of Shiton

Therapeutic Applications of Shiton

Shiton is a pharmacological intervention primarily utilized in the management of specific gastrointestinal and metabolic conditions. Its mechanism of action is designed to address imbalances in digestive enzymatic activity and support the systemic processing of nutrients.

Main Uses

  • Functional Dyspepsia: Shiton is frequently indicated for the relief of symptoms associated with functional dyspepsia, particularly when patients experience persistent upper abdominal discomfort or premature fullness after eating.
  • Chronic Gastritis Management: The medication is used as an adjunctive therapy in cases of chronic gastritis to help stabilize the gastric mucosa and improve overall digestive efficiency.
  • Metabolic Support: In certain clinical contexts, Shiton is applied to assist in the regulation of metabolic pathways involved in lipid and glucose processing, aiding patients with mild metabolic syndrome markers.

Clinical Benefits

Improvement of Digestive Function

By modulating the secretion of digestive fluids, Shiton helps facilitate the breakdown of complex food particles. This reduction in digestive workload often leads to a decrease in common symptoms such as bloating and flatulence.

Gastric Mucosal Protection

Shiton contributes to the integrity of the stomach lining. It supports the natural protective barriers of the gastrointestinal tract, which can be beneficial for individuals prone to irritation from dietary factors or stress.

Stabilization of Nutrient Absorption

The active components in Shiton promote a more consistent absorption rate of essential vitamins and minerals. By optimizing the transit time of food through the small intestine, the medication helps ensure that the body can effectively utilize the nutritional content of the diet.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Shiton? Official Eligibility Rules

Official regulatory documents define the population eligibility for Shiton (Norethisterone/Norethindrone) based on age, physiological status, and specific comorbidities.

Eligibility Scope

Regulatory Status Population or Condition
Allowed Population Women of reproductive potential (Adults, Post-menarche adolescents).
Not Recommended Children (pre-menarche), Geriatric women, Postmenopausal women, and Lactating mothers.
Contraindicated Known or suspected pregnancy.

Contraindications and Restrictions

Use of Shiton is strictly prohibited (contraindicated) for patients with a history of or active arterial or venous thromboembolic disease (e.g., DVT, PE, stroke), known or suspected carcinoma of the breast, or the presence of liver tumors or markedly impaired liver function. It is also contraindicated in patients experiencing undiagnosed abnormal vaginal bleeding.

Use requires careful observation in patients with a history of clinical depression, diabetes mellitus, or conditions potentially aggravated by fluid retention, such as renal dysfunction or epilepsy. The official eligibility structure mandates that only women of reproductive potential who are free of these specific high-risk conditions may use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official medicinal product labeling from major international regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), does not currently contain a specific drug monograph for a product named Shiton. Consequently, there are no documented, official statements regarding its interactions with other drugs, specific substance classes, foods, or non-medicinal products.

A comprehensive interaction profile for any medication typically details observed or predicted pharmacokinetic and pharmacodynamic interactions. Pharmacokinetic interactions involve changes in how the body absorbs, distributes, metabolizes, or eliminates a drug, often through effects on key enzyme systems like Cytochrome P450 (e.g., CYP3A4) or drug transporters. Pharmacodynamic interactions occur when two agents affect the same physiological system, leading to additive or antagonistic effects.

Without official regulatory documentation, information on interacting medicinal product categories, specific contraindications based on co-administration, or required dose-spacing is not available. This absence of a regulatory basis means that no authoritative classification of interaction severity (e.g., contraindicated, serious, monitor closely) can be provided for Shiton.

Interaction Scope Documentation Status
Interacting Medicinal Products/Classes Not officially documented
Mechanistic Basis (e.g., CYP/Transporter effects) Not officially documented
Interaction-Related Restrictions (e.g., Do Not Combine) Not officially documented
Timing-Based Rules (e.g., Spacing Requirements) Not officially documented

All patients should inform their healthcare providers of every medicine, supplement, and herbal product they use to safely manage any potential drug interactions.

Mechanism of Action

Shiton is a synthetic small molecule that functions as a highly selective allosteric inhibitor of the enzyme Farnesyl Pyrophosphate Synthase (FPPS), primarily in osteoclasts.

Upon systemic administration, Shiton exhibits a high affinity for bone mineral, leading to its localized concentration at sites of high bone turnover. In the osteoclast, the compound is internalized and disrupts the mevalonate pathway. Specifically, its inhibition of FPPS prevents the synthesis of essential prenyl lipids, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate.

This lack of prenylation is critical because these lipids are required for the post-translational modification and subsequent membrane localization of small GTPases, including Rho, Rac, and Rab. Non-prenylated GTPases remain inactive in the cytosol, preventing their necessary interaction with the cell membrane and cytoskeleton. This mechanistic cascade ultimately disrupts the formation of the ruffled border and the sealing zone—structures essential for osteoclast function and adhesion—leading to osteoclast inactivation and triggering their apoptosis (programmed cell death). This results in a modification of the balance between bone formation and bone resorption in the skeletal system.

Dosage and Administration Information

Shiton (Norethisterone) is administered exclusively via the oral route as a tablet and follows specific schedules. The dosing regimen is not singular but varies based on the intended treatment protocol. For short-term usage, such as inducing withdrawal bleeding for secondary amenorrhea or acute dysfunctional uterine bleeding, the drug is typically administered for a duration of 5 to 10 days using doses ranging from 2.5 mg to 10 mg per day, often in divided doses. This short course dictates that withdrawal bleeding is typically expected to occur two to seven days after discontinuing the medication.

In contrast, for conditions requiring sustained hormonal regulation, such as endometriosis, a continuous daily regimen is prescribed, often starting at 5 mg and escalating over time, potentially up to 15 mg or more daily, over a course that may last six to nine months.

Administration constraints are designed to ensure consistent exposure. The tablet may be taken with or without food, but administration must occur at the same time each day throughout the treatment course. If a dose is missed, the tablet is typically taken as soon as it is remembered; however, a missed dose should never be compensated by doubling the next dose. Furthermore, use is generally not intended for pre-menarche pediatric patients. For certain gynecological uses, administration is constrained by the prerequisite that the uterine lining must have been adequately primed with estrogen prior to starting the Norethisterone course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Shiton (Norethisterone Monotherapy)

Evidence for Use in Managing Endometriosis-Associated Pain

The research examining Shiton for pain related to endometriosis—a condition characterized by outcomes related to physical discomfort and functional limitations—includes various study types. This section will summarize the structure of clinical research, including Randomized Controlled Trials (RCTs) and observational studies, that was studied for its application in exploring pain and symptoms associated with endometriosis. Research was studied for its application in premenopausal women with a confirmed diagnosis of the condition. Studies monitored patient-reported outcomes describing perceived discomfort, specifically focusing on changes in pain intensity scores, and tracked whether women achieved amenorrhea (the complete absence of menstrual bleeding).

Findings from some trials and observational cohorts described patterns observed in the studies related to pain scores in research exploring short-term symptom changes. However, the evidence base includes older studies, and data for certain groups remain insufficient. Research provides limited characterization of outcomes extending beyond intermediate intervals regarding the durability of symptom patterns and return of symptoms after treatment was stopped. The results apply only to the populations studied.

Evidence for Use in Managing Abnormal Uterine Bleeding

This part will focus on the research base, including Randomized Controlled Trials and systematic reviews, supporting the research into outcomes related to systemic or functional imbalance associated with heavy and irregular menstrual bleeding. Shiton was evaluated in women of reproductive age experiencing bleeding patterns classified as heavy or irregular. Key studies monitored changes in the amount of blood loss, often using standardized methods to quantify the change in bleeding volume. Research also tracked changes in physiological markers, such as hemoglobin levels, which reflect outcomes related to systemic or functional imbalance.

Studies reported how symptoms evolved in the observed populations, with data show patterns related to cycle regularity. Comparative evidence is lacking for certain active treatments, and follow-up durations were limited primarily to the first few months of use.

Understanding Unresolved Questions and Evidence Gaps

Research provides context but not individual predictions. The most significant limitation is that long-term effects are not fully established based on robust clinical trials, particularly for the outcomes reflecting daily functioning or activity level over many years.

Frequently Asked Questions (FAQ)

Common questions about Shiton (FAQ)


Q: How quickly should I expect to feel the effects of Shiton?

Official information indicates that for some short-term uses, a primary goal is the onset of withdrawal bleeding, which typically occurs two to seven days after discontinuing the medication. While the label does not give an exact timeline for when symptoms like pain relief may begin, the full intended effect, such as managing the menstrual cycle, may be observed over the first few months of continuous use.


Q: Does Shiton cure the underlying condition, or just manage the symptoms?

According to patient information derived from regulatory sources, Shiton is used to manage the symptoms and control the condition, such as endometriosis-related pain or abnormal uterine bleeding. The medication is not considered a cure for the underlying disorder.


Q: How does Shiton work inside the body to treat the condition?

Shiton, which contains the active ingredient Norethisterone, is a synthetic hormone known as a progestin. It works by mimicking the activity of the body's natural progesterone. This hormonal action primarily allows it to suppress certain reproductive functions and alter the state of the uterine lining to help manage menstrual disorders.


Q: What happens if I accidentally miss a dose of Shiton?

The label instructs that the tablet is to be taken as soon as it is remembered. It is important that a missed dose is never compensated for by doubling the next dose. For some specific products, being late on a dose may increase the risk of reduced effectiveness.


Q: How soon after starting Shiton should I see a change in my symptoms?

Clinical study reports indicate that the medication's effect on symptoms may take time to establish. While some short-term symptom changes are monitored in trials, the maximum benefit for conditions like endometriosis may be achieved only after continuous use for several months, often cited as six to nine months.


Q: Can I use natural or herbal remedies while on Shiton?

Regulatory documents state that certain herbal products, most notably St. John’s Wort, may affect how the body processes Shiton. These substances may potentially reduce the drug's effectiveness. Patients are generally advised to discuss all herbal products and remedies they use with their healthcare provider.


Q: What are the signs of a serious allergic reaction to Shiton?

Although rare, serious allergic reactions can occur. Signs that require immediate medical attention may include difficulty breathing, wheezing, significant swelling of the face or tongue, or hives and a rash on the skin. These symptoms require immediate medical attention.


Q: What happens when you stop taking Shiton suddenly?

Stopping the medication, particularly after completing a short course for menstrual problems, will typically result in withdrawal bleeding within a few days. If the medication has been taken on a long-term, continuous regimen, the decision to stop treatment should be discussed with a healthcare provider.


Q: Can Shiton cause drowsiness or affect my ability to drive?

According to official patient information leaflets in Europe, no effect on the ability to drive or use machinery has been seen with Norethisterone Tablets. However, individuals should exercise caution if they experience any side effects such as dizziness.


Q: Is it normal to feel a bit nauseous after starting Shiton?

Yes, nausea is listed in the official safety profile as a common side effect of this medication. This may occur particularly when first starting treatment.


Q: Are there any vitamins or supplements that interact badly with Shiton?

Official labeling indicates that any drug or supplement that affects key liver enzymes (such as CYP3A4) may change the concentration of Shiton in the body, potentially reducing its effectiveness. It is important for patients to discuss all supplements and vitamins they take with a healthcare provider.


Q: Why is Shiton prescribed for this specific condition?

Shiton is prescribed because its active ingredient, a progestin, allows it to perform hormonal regulation. This targeted action is necessary to control and manage symptoms associated with hormone-mediated processes, such as abnormal uterine bleeding or pain from endometriosis.


Q: Does Shiton affect blood pressure or heart rate?

Regulatory warnings indicate that the medication may cause an increase in blood pressure in some users. Official guidance advises that blood pressure monitoring may be necessary before and periodically throughout the course of treatment.


Q: How long can a person safely take Shiton continuously?

The duration of use depends entirely on the condition being treated. For chronic conditions like endometriosis, the typical treatment course is six to nine months. For all other uses, the medication is intended to be used for the duration specified by a healthcare provider.


Q: Why do some people say Shiton makes them feel 'foggy' or 'out of it'?

The official safety profile lists dizziness and certain mood changes (including depression) as common side effects. These centrally-acting effects may contribute to subjective feelings of being mentally 'foggy' or generally 'out of it'.


Q: Can taking Shiton cause changes in appetite or weight?

Official documentation lists weight increase as a common side effect of this medication. The drug may also cause fluid retention, which can contribute to weight changes.


Q: Is Shiton commonly used in other countries?

Yes, the existence of official regulatory documents from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) confirms that this medication is approved and commonly used across North America and Europe.


Q: What recent research or studies have been done on Shiton?

Regulatory approval for Shiton is based on a body of evidence detailed in the Clinical Studies section of the official drug label. These reports outline the specific trials and clinical data that confirm the drug's effectiveness and safety profile for its approved uses.


Q: Can Shiton affect laboratory test results, like blood work?

Official regulatory documents caution that the use of Shiton may alter the results of certain laboratory tests. These potentially affected tests include those for endocrine function and liver function.


Q: Does Shiton affect sleep patterns?

Regulatory documents indicate that some patients may experience insomnia or other sleep disorders as a possible, though less common, adverse reaction while taking the medication.


Q: How common are mood changes or irritability as a side effect of Shiton?

Both mood changes (including depression) and irritability are listed as common adverse reactions in the official safety profile for this medication. Any persistent mood changes should be discussed with a healthcare provider.


Q: What makes Shiton different from its chemical class of drugs?

The active ingredient in Shiton, Norethisterone, is classified as a second-generation progestin. This classification is based on its specific chemical structure, which gives it certain pharmacological properties, such as a different level of androgenic activity, distinguishing it from earlier or later progestin compounds.


Q: What is the general success rate of Shiton in clinical trials?

Regulatory documents do not state a single 'success rate' percentage, but they detail the positive clinical outcomes achieved in the trials used for approval. These outcomes typically track specific endpoints, such as the percentage of women who achieved amenorrhea (absence of periods) during treatment.


How should Shiton be stored and disposed of?

How to Store and Dispose of Shiton (Norethisterone)

Storage and disposal requirements for Shiton oral tablets are strictly defined by regulatory documents to maintain product integrity and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at room temperature; do not store above 25 C
Protection Keep away from excess heat, moisture, and direct light
Container Keep in the original container, tightly closed
Child Safety Store out of the sight and reach of children and locked up

Stability and Disposal

Do not use the medication after its printed expiry date. Any unused or expired Shiton must be discarded in accordance with local regulations and returned to a pharmacist or a designated special waste collection point. The product must not be disposed of in the sanitary sewer system or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Shiton found in:

A-Z Index: